Advertisement
U.S. markets open in 52 minutes

BioXcel Therapeutics, Inc. (BTAI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1700+0.0200 (+0.63%)
At close: 04:00PM EST
3.1300 -0.04 (-1.26%)
Pre-Market: 08:35AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.1500
Open3.3500
Bid0.0000 x 1400
Ask0.0000 x 1000
Day's Range3.1200 - 3.3200
52 Week Range1.9100 - 32.8700
Volume832,334
Avg. Volume1,555,909
Market Cap96.311M
Beta (5Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)-7.3600
Earnings DateMar 07, 2024 - Mar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BTAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioXcel Therapeutics, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Insider Monkey

    15 Hot Penny Stocks On the Move

    In this article, we will take a detailed look at the 15 Hot Penny Stock On the Move. For a quick overview of such stocks, read our article 5 Hot Penny Stock On the Move. Strong inflation data from January and the Fed’s indications that it would take its time before initiating rate cuts threw cold […]

  • GlobeNewswire

    BioXcel Therapeutics Announces Termination of Proposed Public Offering

    NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024. As

  • GlobeNewswire

    BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

    Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability BXCL701 is an investigational, oral innate immune activator designed to inflame the tumor microenvironment and augment CPI activity Company to discuss registration path at upcoming meeting with FDA NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopha